310
Views
6
CrossRef citations to date
0
Altmetric
Brief Report

A case of asthma with Behcet’s disease: successful treatment with omalizumab and its effects on recurrent aphthous lesions

&
Pages 379-382 | Received 17 Dec 2019, Accepted 24 Jun 2020, Published online: 07 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Arzu Didem Yalcin & Ata Nevzat Yalcin. (2021) Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology 43:1, pages 1-7.
Read now

Articles from other publishers (5)

Kamel Hamzaoui & Agnès Hamzaoui. 2023. Translational Autoimmunity. Translational Autoimmunity 487 507 .
Paolo Del Barba, Federica Del Tedesco, Giulio Frontino, Maria Pia Guarneri, Riccardo Bonfanti & Graziano Barera. (2022) Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes. Frontiers in Immunology 13.
Crossref
McKella Sylvester, Aran Son & Daniella M. Schwartz. (2022) The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations. Frontiers in Immunology 13.
Crossref
Jingjing Chen & Xu Yao. (2021) A Contemporary Review of Behcet’s Syndrome. Clinical Reviews in Allergy & Immunology 61:3, pages 363-376.
Crossref
Xue-Jun Kong, Cullen Clairmont & Bryan Wang. (2021) Case Report: Off-Label Use of Omalizumab in a 6-Year-Old Boy With ASD Ameliorated Severe Allergic Rhinitis and Subsequently Improved Behavioral Symptoms. Frontiers in Pediatrics 9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.